European Pharmaceutical Review

MAY 14, 2024

At its Le Trait site in Normandy, Sanofi added that it will devote €100 million for new capacity for biologics formulation, filling, device assembly and packaging. Sanofi shared that it plans to launch in 2025. An investment of €250 million will used to build Europe’s largest flu vaccine production unit in Val de Reuil.

Vaccines 98

Vaccines Packaging 98

pharmaphorum

DECEMBER 13, 2021

It started with two Covid-19 vaccines – 2021 is the year interest in mRNA therapeutics boomed, reports Katrina Megget. The Covid-19 pandemic showed what could be done with resources and collaboration to accelerate the development of vaccines. There are multiple other mRNA vaccines that are being developed.

Vaccines 105

Vaccines Packaging 105

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Vaccines 52

Vaccines Packaging Immunization FDA 52

Pharmaceutical Technology

NOVEMBER 1, 2022

“The medicines regulators in Europe have a strategy for 2025 where the second pillar is data and digitalisation, so we are trying to transform medicines regulation to be data-driven,” says Peter Arlett, Head of Data Analytics and Methods Task Force at EMA. Arlett explains that Darwin EU is playing a collaborative role in this goal.

Medical Records 111

Medical Records Packaging Vaccines 111

Pharmaceutical Technology

NOVEMBER 22, 2022

The Chinese government announced its ten-year 'Made in China 2025' strategic plan in 2015, which aimed to make the country a global leader in several high-tech industries. These industries unexpectedly also included biotech, which was not a particularly strong area for Chinese manufacturing, which is more recognised for generics production.

FDA 64

FDA Packaging Vaccines 64

ISPE

OCTOBER 26, 2022

We defined the path forward for 2023–2025 after a final round of consultations with the Board advisors in July. In addition, we took the Board on tours of Vetter’s facilities for sterile products and through all the production steps: compounding to fill-finish to automated visual inspection and secondary packaging.

Packaging 52

Packaging Compounding Communication Vaccines 52

ISPE

SEPTEMBER 11, 2023

4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52